Viking Therapeutics Files Routine 8-K for Regulatory Disclosure
Ticker: VKTX · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1607678
Sentiment: neutral
Topics: 8-K filing, regulatory filing, disclosure
Related Tickers: VKTR
TL;DR
**Viking Therapeutics filed a standard 8-K today, but this document itself doesn't disclose any specific new material events.**
AI Summary
Viking Therapeutics, Inc. filed a Form 8-K with the SEC on February 27, 2024, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. This filing, identified by accession number 0000950170-24-020616, indicates a routine regulatory update. The document itself does not disclose specific new material events or financial figures, primarily serving as a procedural compliance filing.
Why It Matters
This filing serves as a procedural update, indicating Viking Therapeutics, Inc. is complying with SEC disclosure requirements. Without specific event details, its immediate market impact is minimal, but it signals potential forthcoming information.
Risk Assessment
Risk Level: low — The filing is a routine regulatory disclosure and does not contain information about specific events that would inherently increase or decrease risk.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — registrant
- SEC (company) — regulatory body
- February 27, 2024 (date) — date of report
FAQ
What company filed this Form 8-K?
Viking Therapeutics, Inc. filed this Form 8-K.
What was the date of the earliest event reported in this filing?
The date of the earliest event reported was February 27, 2024.
What specific items were disclosed in this 8-K?
This 8-K disclosed Item Information regarding Regulation FD Disclosure and Financial Statements and Exhibits.
What is the Central Index Key (CIK) for Viking Therapeutics, Inc.?
The CIK for Viking Therapeutics, Inc. is 0001607678.
What is the business phone number for Viking Therapeutics, Inc.?
The business phone number for Viking Therapeutics, Inc. is (858) 704-4660.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-02-27 07:04:52
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20240227.htm (8-K) — 41KB
- vktx-ex99_1.htm (EX-99.1) — 82KB
- img201808844_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-020616.txt ( ) — 255KB
- vktx-20240227.xsd (EX-101.SCH) — 30KB
- vktx-20240227_htm.xml (XML) — 5KB
01. Regulation FD
Item 7.01. Regulation FD. On February 27, 2024, Viking Therapeutics, Inc. issued a press release announcing results from its Phase 2 VENTURE trial of VK2735 in patients with obesity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated February 27, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIKING THERAPEUTICS, INC. Date: February 27, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)